German APERIO® Hybrid Post- Market Clinical Follow-up Study~APERIO® Hybrid PMCF Study- Thrombectomy device for flow restoration in vessels of patients experiencing acute ischemic stroke~Study Type: prospective, multicenter, single-armed, open-label~Participants: 8 participating centers in Germany~PI: Dr. Christian Mathys, Evangelisches Krankenhaus Oldenburg, Germany~Estimated Enrolment: 430 patients treated with APERIO® HYBRID Thrombectomy~Device as a result of an acute stroke~Follow up: 3 months~Estimated Final Assessment: End of 2022
This is a prospective, multicenter, single-arm, open-label, national Post-Market Clinical Follow-up study to collect comprehensive information on technical and clinical success and safety of the use of APERIO® Hybrid Thrombectomy Device in clinical practice. APERIO® Hybrid Thrombectomy Device will be used within its approved indication.